Soleno治疗局内部人员不顾购买评级和第三阶段试验的进展,出售了数百万股。 Soleno Therapeutics insiders sold millions in shares despite a buy rating and Phase III trial progress for a new treatment.

内部人士Patricia C. Hirano和James H. Mackaness最近出售股票,共计265 156美元和6 292 791美元。 Soleno Therapeutics (SLNO) insiders Patricia C. Hirano and James H. Mackaness recently sold shares, totaling $265,156 and $6,292,791 respectively. 该公司的股票获得收购评级,HC Wainwright公司在进入Prader-Willi综合症治疗第三阶段试验的主要候选人之后,将价格目标提高到100美元。 The company's stock received a buy rating with a price target increase to $100 by HC Wainwright, following its lead candidate entering Phase III trials for Prader-Willi Syndrome treatment. 尽管第一季度的收益低于预期，但 Soleno Therapeutics 的市值为 33.8 亿美元。 Despite missing Q1 earnings expectations, Soleno Therapeutics has a market cap of $3.38 billion.